Home » Authors » Trista Morrison

Articles by Trista Morrison

No Public Funds or Partners: Can Istodax Be New Approval Model?

Nov. 16, 2009

By Trista Morrison

Maxygen Buying Back Stock; Analysts Say No Trend Here

Nov. 16, 2009

By Trista Morrison

Maxygen Inc. on Friday became the latest member of a very small biotech cadre that is returning cash to shareholders. (BioWorld Today)

Altus Shares Hit Rock Bottom as Firm Files for Bankruptcy

Nov. 13, 2009

By Trista Morrison

BioVex's $70M Series F to Fund Pivotal OncoVex Melanoma Trial

Nov. 11, 2009

By Trista Morrison

Trius and Alimera Join Growing Roster of Biotech IPO Hopefuls

Nov. 10, 2009

By Trista Morrison

Returning Money to Investors: Still the Exception, Not the Rule

Nov. 9, 2009

By Trista Morrison

Genmab Still Cutting: 300 Jobs and Manufacturing Next to Go

Nov. 9, 2009

By Trista Morrison

NewCo News: Kalos Hits Financing Trail for Peptide-Based MAPK Inhibitor

Nov. 5, 2009

By Trista Morrison

HCV Vaccines, TLRs Advance Away from Protease Spotlight

Nov. 4, 2009

By Trista Morrison

HCV Vaccines, TLRs Advance Away from Protease Spotlight

Nov. 2, 2009

By Trista Morrison

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...